The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the superior commercial and clinical portfolios of the Indianapolis company ...

U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral ...

Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...

We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a ...

Now some doctors are trying GLP-1 drugs — popular medications for weight-loss and Type 2 diabetes — as part of lymphedema ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

The Jesuits have a saying for how to win a recruit for life: ‘Give me a child until he is seven and I will show you the adult.’ ...

supported by long-term safety data with more than 33 million patient years of exposure. Novo Nordisk submitted a label extension application for Ozempic to the European Medicines Agency (EMA ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets, valued at more than $100 billion. Each of them has advantages, as well as dark spots in the pipeline of ...

After posting over 400 crores globally during its original box office run, Devara has arrived in the new market during phase two of its theatrical release. Yesterday, the magnum opus was released ...

Novo Nordisk on Saturday said its diabetes pill ... But the trial was "clearly" designed to examine the cardiovascular rather than kidney benefits of the pill, Gough said. Ozempic is already ...

Copenhagen, DENMARK — Novo Nordisk defended disappointing trial ... The once darling stock is now down more than 50% from its 2024 highs. The Danish pharmaceutical giant faced pushback once ...